Access to the webcast via http://www.topotarget.com or via telephone with the following dial in details: (no pincode is needed)
European and domestic participants dial: +45-327-147-67
US participants dial: +1-718-354-1226
It will be possible to ask questions by telephone or by emailing email@example.com
The webcast will be held in English. An archive of the webcast will be posted on http://www.topotarget.com 30 minutes after the end of the live transmission. The archive will be available on the company's website for 3 months.
Belinostat is a promising small molecule HDAC inhibitor being investigated for its role in the treatment of a wide range of solid tumors and hematologic malignancies either as a single-agent, or in combination with other active anti-cancer agents, including carboplatin, paclitaxel, cis-retinoic acid, azacitidine and Velcade(R) (bortezomib) for injection. HDAC inhibitors represent a new mechanistic class of anti-cancer therapeutics that target HDAC enzymes, and have been shown to arrest growth of cancer cells (including drug resistant subtypes); induce apoptosis, or programmed cell death; promote differentiation; inhibit angiogenesis; and sensitize cancer cells to overcome drug resistance when used in combination with other anti-cancer agents.
Intravenous belinostat is currently being evaluated in multiple
clinical trials as a potential treatment for cutaneous and peripheral
T-cell lymphomas, B-cell lymphomas, AML, mesothelioma, soft tissue sarcoma,
MDS, and liver, colorectal, and ovarian cancers, either alone or in
combination with anti-cancer therapies. An oral formulation of belinostat
is also being evaluated in a Phase I clinical trial for patients with
|SOURCE TopoTarget A/S|
Copyright©2008 PR Newswire.
All rights reserved